WST analyst estimates
West Pharmaceutical (WST) analyst ratings, the average price target and its range, and every firm's latest call.
WST analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | West Pharmaceutical price target raised to $440 from $400 at Barclays | $440.00 |
| Sep 22, 2026 | Morgan Stanley | West Pharmaceutical upgraded to Overweight from Equal Weight at Morgan Stanley | $400.00 |
| Sep 9, 2026 | UBS | West Pharmaceutical assumed with a Buy at UBS | $415.00 |
| Jul 27, 2026 | Evercore ISI | West Pharmaceutical price target raised to $425 from $410 at Evercore ISI | $425.00 |
| Jul 13, 2026 | BNP Paribas | West Pharmaceutical initiated with an Outperform at BNP Paribas | $447.00 |
| Jul 9, 2026 | Morgan Stanley | West Pharmaceutical price target raised to $365 from $325 at Morgan Stanley | $365.00 |
| Jul 6, 2026 | Evercore ISI | West Pharmaceutical price target raised to $410 from $390 at Evercore ISI | $410.00 |
| Jul 2, 2026 | KeyBanc | West Pharmaceutical price target raised to $390 from $350 at KeyBanc | $390.00 |
| Jun 9, 2026 | Barclays | Barclays upgrades West Pharmaceutical on 'material' upside to estimates | $400.00 |
| Apr 27, 2026 | Barclays | West Pharmaceutical price target raised to $310 from $275 at Barclays | $310.00 |
| Apr 27, 2026 | Morgan Stanley | West Pharmaceutical price target raised to $315 from $285 at Morgan Stanley | $315.00 |
| Feb 13, 2026 | Barclays | West Pharmaceutical price target lowered to $265 from $325 at Barclays | $265.00 |
| Feb 13, 2026 | Deutsche Bank | West Pharmaceutical price target raised to $315 from $310 at Deutsche Bank | $315.00 |
| Feb 13, 2026 | UBS | West Pharmaceutical price target lowered to $340 from $355 at UBS | $340.00 |
| Feb 10, 2026 | Jefferies | West Pharmaceutical price target lowered to $295 from $365 at Jefferies | $295.00 |
- 9 firms rate WST: 9 buy, 0 hold, 0 sell.
- The average price target is $419.50 from 6 analysts, from $390.00 to $447.00.
Updated 2026-11-03 00:00 UTC